Vol. 4, Issue 1-2, 2022May 12, 2022 BST
Safety and Efficacy of Elective Switch from Nilotinib to Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia
Safety and Efficacy of Elective Switch from Nilotinib to Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia
Ali Ibrahim, Nour Moukalled, Rami Mahfouz, Jean El Cheikh, Ali Bazarbachi, Iman Abou Dalle,
Ibrahim, Ali, Nour Moukalled, Rami Mahfouz, Jean El Cheikh, Ali Bazarbachi, and Iman Abou Dalle. 2022. “Safety and Efficacy of Elective Switch from Nilotinib to Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia.” Clinical Hematology International 4 (1–2): 30–34. https://doi.org/10.1007/s44228-022-00001-x.